This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, speaks during a Senate Senate Health, Education, Labor, and Pensions Committee hearing in Washington on Sept. 23, 2020. Graeme Jennings/Pool via Reuters
The announcement of Pfizer’s newly developed vaccine trial success rate may allow the public to be more accepting of getting the vaccine, director of the National Institute of Allergy and Infectious Diseases (NIAID) said.
Pfizer recently announced that the vaccine it had developed had a 90 percent efficacy rate for its trial in a press release on Nov. 9.
